Previous 10 | Next 10 |
SOUTH SAN FRANCISCO, Calif., July 02, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced grants of stock ...
Assembly Biosciences (NASDAQ: ASMB ) initiates Phase 2 trial of its nex-gen core inhibitor, ABI-H2158 in combination with entecavir, vs. placebo+entecavir. More news on: Assembly Biosciences, Inc., Healthcare stocks news, Read more ...
SOUTH SAN FRANCISCO, Calif., June 25, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced the initiation o...
Regeneron Receives FDA Nod for Dupixent Regeneron Pharmaceuticals ( REGN ) reported that the FDA has given its approval for a 300 mg single-dose prefilled pen formulation of Dupixent. The drug is now authorized for treating certain patients at least 12 years old with atopic dermatitis, a...
SOUTH SAN FRANCISCO, Calif., June 22, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced that preclinical...
Assembly Biosciences (NASDAQ: ASMB ) announces that it has regained global rights to all microbiome gastrointestinal (GI) programs out-licensed to AbbVie (NYSE: ABBV ) unit Allergan in January 2017. Its decision was not based on efficacy or safety issues. More news on: Assembly Bioscie...
-- Process to explore strategic alternatives underway -- SOUTH SAN FRANCISCO, Calif., June 18, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases as...
SOUTH SAN FRANCISCO, Calif., June 01, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced grants of induce...
-- Expert Virologist and Biologist William Delaney, PhD joins as Chief Scientific Officer, Virology -- -- EVP and CSO of Virology Operations Richard Colonno, PhD to retire -- SOUTH SAN FRANCISCO, Calif., May 27, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. ...
SOUTH SAN FRANCISCO, Calif., May 26, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced that John McHutch...
News, Short Squeeze, Breakout and More Instantly...
Assembly Biosciences Inc. Company Name:
ASMB Stock Symbol:
NASDAQ Market:
Assembly Biosciences Inc. Website:
2024-07-16 14:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
– Data from both ABI-5366 and ABI-1179, novel long-acting helicase-primase inhibitor candidates for recurrent genital herpes, to be presented – – Poster presentation highlights key preclinical data from ABI-5366 supporting its entry into ongoing Phase 1a/b clinical ...
SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced that the first participant has been dosed in the Phase 1b trial of ABI-4334, a nex...